Current strategies for the treatment of inborn errors of metabolism

Michael J. Gambello; Hong Li

doi:10.1016/j.jgg.2018.02.001

Volume 45 Issue 2

Feb. 2018

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2018 > 45(2): 61-70

PDF( 858 KB)

Current strategies for the treatment of inborn errors of metabolism

doi: 10.1016/j.jgg.2018.02.001

Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA

More Information

Corresponding author: E-mail address: Hong.Li@emory.edu (Hong Li)
Received Date: 2017-10-06
Accepted Date: 2018-02-11
Rev Recd Date: 2017-11-14

Available Online: 2018-02-14

Publish Date: 2018-02-20

Abstract

Abstract

Inborn errors of metabolism (IEMs) are a large group of inherited disorders characterized by disruption of metabolic pathways due to deficient enzymes, cofactors, or transporters. The rapid advances in the understanding of the molecular pathophysiology of many IEMs, have led to significant progress in the development of many new treatments. The institution and continued expansion of newborn screening provide the opportunity for early treatment, leading to reduced morbidity and mortality. This review provides an overview of the diverse therapeutic approaches and recent advances in the treatment of IEMs that focus on the basic principles of reducing substrate accumulation, replacing or enhancing absent or reduced enzyme or cofactor, and supplementing product deficiency. In addition, the challenges and obstacles of current treatment modalities and future treatment perspectives are reviewed and discussed.
- Inborn errors of metabolism,
- Treatment,
- Dietary therapy,
- Enzyme replacement therapy,
- Substrate reduction therapy,
- Pharmacological chaperone therapy

FullText(HTML)

References(92)

References

[1]	Al Teneiji, A., Bruun, T.U., Cordeiro, D. et al. Phenotype, biochemical features, genotype and treatment outcome of pyridoxine-dependent epilepsy Metab. Brain Dis., 32 (2017),pp. 443-451
[2]	Aldenhoven, M., Wynn, R.F., Orchard, P.J. et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study Blood, 125 (2015),pp. 2164-2172
[3]	Alfadhel, M., Al-Thihli, K., Moubayed, H. et al. Drug treatment of inborn errors of metabolism: a systematic review Arch. Dis. Child., 98 (2013),pp. 454-461
[4]	Badell, I.R., Hanish, S.I., Hughes, C.B. et al. Domino liver transplantation in maple syrup urine disease: a case report and review of the literature Transplant. Proc., 45 (2013),pp. 806-809
[5]	Balwani, M., Burrow, T.A., Charrow, J. et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States Mol. Genet. Metab., 117 (2016),pp. 95-103
[6]	Barshes, N.R., Vanatta, J.M., Patel, A.J. et al. Evaluation and management of patients with propionic acidemia undergoing liver transplantation: a comprehensive review Pediatr. Transplant., 10 (2006),pp. 773-781
[7]	Barton, N.W., Brady, R.O., Dambrosia, J.M. et al. Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher's disease N. Engl. J. Med., 324 (1991),pp. 1464-1470
[8]	Belmatoug, N., Di Rocco, M., Fraga, C. et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe Eur. J. Intern. Med., 37 (2017),pp. 25-32
[9]	Bendikov-Bar, I., Maor, G., Filocamo, M. et al. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase Blood Cells Mol. Dis., 50 (2013),pp. 141-145
[10]	Benjamin, E.R., Della Valle, M.C., Wu, X. et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat Genet. Med., 19 (2017),pp. 430-438
[11]	Berry, S.A., Lichter-Konecki, U., Diaz, G.A. et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes Mol. Genet. Metab., 112 (2014),pp. 17-24
[12]	Biffi, A., Montini, E., Lorioli, L. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy Science, 341 (2013),p. 1233158
[13]	Boy, N., Muhlhausen, C., Maier, E.M. et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision J. Inherit. Metab. Dis., 40 (2017),pp. 75-101
[14]	Boyer, S.W., Barclay, L.J., Burrage, L.C. Inherited metabolic disorders: aspects of chronic nutrition management Nutr. Clin. Pract., 30 (2015),pp. 502-510
[15]	Bublil, E.M., Majtan, T., Park, I. et al. Enzyme replacement with PEGylated cystathionine beta-synthase ameliorates homocystinuria in murine model J. Clin. Invest., 126 (2016),pp. 2372-2384
[16]	Chiesa, R., Wynn, R.F., Veys, P. Haematopoietic stem cell transplantation in inborn errors of metabolism Curr. Opin. Hematol., 23 (2016),pp. 530-535
[17]	, van Karnebeek, C.D., Al-Hertani, W., Shuen, A.Y. et al. Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: neurodevelopmental outcome Mol. Genet. Metab., 116 (2015),pp. 35-43
[18]	Cox, T.M., Drelichman, G., Cravo, R. et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial Lancet, 385 (2015),pp. 2355-2362
[19]	Daniotti, M., la Marca, G., Fiorini, P. et al. New developments in the treatment of hyperammonemia: emerging use of carglumic acid Int. J. Gen. Med., 4 (2011),pp. 21-28
[20]	Di Rocco, M., Barone, R., Madeo, A. et al. Miglustat does not prevent neurological involvement in Niemann Pick C disease Pediatr. Neurol., 53 (2015),p. e15
[21]	Diaz, G.A., Krivitzky, L.S., Mokhtarani, M. et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate Hepatology, 57 (2013),pp. 2171-2179
[22]	Duffner, P.K., , Erbe, R.W., Patterson, M.C. et al. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York Genet. Med., 11 (2009),pp. 450-454
[23]	Eichler, F., Duncan, C., Musolino, P.L. et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy N. Engl. J. Med., 377 (2017),pp. 1630-1638
[24]	Escolar, M.L., Poe, M.D., Provenzale, J.M. et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease N. Engl. J. Med., 352 (2005),pp. 2069-2081
[25]	Fecarotta, S., Romano, A., Della Casa, R. et al. Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C Orphanet J. Rare Dis., 10 (2015),p. 22
[26]	Fratantoni, J.C., Hall, C.W., Neufeld, E.F. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts Science, 162 (1968),pp. 570-572
[27]	Gamez, A., Wang, L., Sarkissian, C.N. et al. Structure-based epitope and PEGylation sites mapping of phenylalanine ammonia-lyase for enzyme substitution treatment of phenylketonuria Mol. Genet. Metab., 91 (2007),pp. 325-334
[28]	Gamez, A., Wang, L., Straub, M. et al. Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase Mol. Ther., 9 (2004),pp. 124-129
[29]	Ginocchio, V.M., Brunetti-Pierri, N. Progress toward improved therapies for inborn errors of metabolism Hum. Mol. Genet., 25 (2016),pp. R27-R35
[30]	Giugliani, R., Vieira, T.A., Carvalho, C.G. et al. Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I Mol. Genet. Metab. Rep, 10 (2017),pp. 61-66
[31]	Haberle, J. Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency Therapeut. Clin. Risk Manag., 7 (2011),pp. 327-332
[32]	Haberle, J., Boddaert, N., Burlina, A. et al. Suggested guidelines for the diagnosis and management of urea cycle disorders Orphanet J. Rare Dis., 7 (2012),p. 32
[33]	Ho, G., Christodoulou, J. Phenylketonuria: translating research into novel therapies Transl. Pediatr., 3 (2014),pp. 49-62
[34]	Ho, G., Ueda, K., Houben, R.F. et al. Metabolic Diet App Suite for inborn errors of amino acid metabolism Mol. Genet. Metab., 117 (2016),pp. 322-327
[35]	Hoskins, J.A., Holliday, S.B., Greenway, A.M. The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study Biomed. Mass Spectrom., 11 (1984),pp. 296-300
[36]	Hughes, D.A., Nicholls, K., Shankar, S.P. et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study J. Med. Genet., 54 (2017),pp. 288-296
[37]	Ito, S., Barrett, A.J. Gauchers disease–a reappraisal of hematopoietic stem cell transplantation Pediatr. Hematol. Oncol., 30 (2013),pp. 61-70
[38]	Kasahara, M., Horikawa, R., Tagawa, M. et al. Current role of liver transplantation for methylmalonic acidemia: a review of the literature Pediatr. Transplant., 10 (2006),pp. 943-947
[39]	Kasahara, M., Sakamoto, S., Horikawa, R. et al. Living donor liver transplantation for pediatric patients with metabolic disorders: the Japanese multicenter registry Pediatr. Transplant., 18 (2014),pp. 6-15
[40]	Kasapkara, C.S., Kangin, M., Tas, F.F. et al. Unusual cause of hyperammonemia in two cases with short-term and long-term valproate therapy successfully treated by single dose carglumic acid J. Pediatr. Neurosci., 8 (2013),pp. 250-252
[41]	Kishnani, P.S., Beckemeyer, A.A. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond Pediatr. Endocrinol. Rev., 12 (2014),pp. 114-124
[42]	Kolker, S., Boy, S.P., Heringer, J. et al. Complementary dietary treatment using lysine-free, arginine-fortified amino acid supplements in glutaric aciduria type I - A decade of experience Mol. Genet. Metab., 107 (2012),pp. 72-80
[43]	Kruger, W.D. Cystathionine beta-synthase deficiency: of mice and men Mol. Genet. Metab., 121 (2017),pp. 199-205
[44]	Lachmann, R.H., te Vruchte, D., Lloyd-Evans, E. et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C Neurobiol. Dis., 16 (2004),pp. 654-658
[45]	Laemmle, A., Stricker, T., Haberle, J. Switch from sodium phenylbutyrate to glycerol phenylbutyrate improved metabolic stability in an adolescent with ornithine transcarbamylase deficiency JIMD Rep., 31 (2017),pp. 11-14
[46]	Lanpher, B., Brunetti-Pierri, N., Lee, B. Inborn errors of metabolism: the flux from Mendelian to complex diseases Nat. Rev. Genet., 7 (2006),pp. 449-460
[47]	Larochelle, J., Alvarez, F., Bussieres, J.F. et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec Mol. Genet. Metab., 107 (2012),pp. 49-54
[48]	Lichter-Konecki, U., Diaz, G.A., , Feigenbaum, A. et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate Mol. Genet. Metab., 103 (2011),pp. 323-329
[49]	Lindstedt, S., Holme, E., Lock, E.A. et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase Lancet, 340 (1992),pp. 813-817
[50]	Lu, J.Z., Hui, E.K., Boado, R.J. et al. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase Bioconjugate Chem., 21 (2010),pp. 151-156
[51]	Lukina, E., Watman, N., Arreguin, E.A. et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1 Blood, 116 (2010),pp. 893-899
[52]	Lukina, E., Watman, N., Dragosky, M. et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment Blood Cells Mol. Dis., 53 (2014),pp. 274-276
[53]	Macauley, S.L. Combination therapies for lysosomal storage diseases: a complex answer to a simple problem Pediatr. Endocrinol. Rev., 13 (2016),pp. 639-648
[54]	Masurel-Paulet, A., Poggi-Bach, J., Rolland, M.O. et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients J. Inherit. Metab. Dis., 31 (2008),pp. 81-87
[55]	Matalonga, L., Gort, L., Ribes, A. Small molecules as therapeutic agents for inborn errors of metabolism J. Inherit. Metab. Dis., 40 (2017),pp. 177-193
[56]	Matoori, S., Leroux, J.C. Recent advances in the treatment of hyperammonemia Adv. Drug Deliv. Rev., 90 (2015),pp. 55-68
[57]	Mauer, M., Sokolovskiy, A., Barth, J.A. et al. J. Med. Genet., 54 (2017),pp. 781-786
[58]	McGuire, B.M., Zupanets, I.A., Lowe, M.E. et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis Hepatology, 51 (2010),pp. 2077-2085
[59]	Miano, M., Lanino, E., Gatti, R. et al. Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation Bone Marrow Transplant., 27 (2001),pp. 747-751
[60]	Mohan, N., Karkra, S., Rastogi, A. et al. Living donor liver transplantation in maple syrup urine disease - case series and world's youngest domino liver donor and recipient Pediatr. Transplant., 20 (2016),pp. 395-400
[61]	Morioka, D., Kasahara, M., Takada, Y. et al. Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University Liver Transplant., 11 (2005),pp. 1332-1342
[62]	Muntau, A.C., Leandro, J., Staudigl, M. et al. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators J. Inherit. Metab. Dis., 37 (2014),pp. 505-523
[63]	Mynarek, M., Tolar, J., Albert, M.H. et al. Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients Bone Marrow Transplant., 47 (2012),pp. 352-359
[64]	Narita, A., Shirai, K., Itamura, S. et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study Ann. Clin. Transl. Neurol., 3 (2016),pp. 200-215
[65]	O'Kane, R.L., Vina, J.R., Simpson, I. et al. Am. J. Physiol. Endocrinol. Metab., 291 (2006),pp. E412-E419
[66]	Oishi, K., Arnon, R., Wasserstein, M.P. et al. Liver transplantation for pediatric inherited metabolic disorders: considerations for indications, complications, and perioperative management Pediatr. Transplant., 20 (2016),pp. 756-769
[67]	Patterson, M.C., Vecchio, D., Jacklin, E. et al. Long-term miglustat therapy in children with Niemann-Pick disease type C J. Child Neurol., 25 (2010),pp. 300-305
[68]	Pey, A.L., Perez, B., Desviat, L.R. et al. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations Hum. Mutat., 24 (2004),pp. 388-399
[69]	Pietz, J., Kreis, R., Rupp, A. et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria J. Clin. Invest., 103 (1999),pp. 1169-1178
[70]	Prince, W.S., McCormick, L.M., Wendt, D.J. et al. Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase J. Biol. Chem., 279 (2004),pp. 35037-35046
[71]	Ries, M. Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016) J. Inherit. Metab. Dis., 40 (2017),pp. 343-356
[72]	Rocha, J.C., Martel, F. Large neutral amino acids supplementation in phenylketonuric patients J. Inherit. Metab. Dis., 32 (2009),pp. 472-480
[73]	Roe, C.R., Brunengraber, H. Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: review of 15 years experience Mol. Genet. Metab., 116 (2015),pp. 260-268
[74]	Schneller, J.L., Lee, C.M., Bao, G. et al. Genome editing for inborn errors of metabolism: advancing towards the clinic BMC Med., 15 (2017),p. 43
[75]	Singh, R.H., Cunningham, A.C., Mofidi, S. et al. Updated, web-based nutrition management guideline for PKU: an evidence and consensus based approach Mol. Genet. Metab., 118 (2016),pp. 72-83
[76]	Smith, W., Diaz, G.A., Lichter-Konecki, U. et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate J. Pediatr., 162 (2013),pp. 1228-1234
[77]	Solomon, M., Muro, S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives Adv. Drug Deliv. Rev., 118 (2017),pp. 109-134
[78]	Sondhi, D., Johnson, L., Purpura, K. et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis Hum. Gene Ther. Meth., 23 (2012),pp. 324-335
[79]	Strauss, K.A., Brumbaugh, J., Duffy, A. et al. Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx Mol. Genet. Metab., 104 (2011),pp. 93-106
[80]	Suryawan, A., Hawes, J.W., Harris, R.A. et al. A molecular model of human branched-chain amino acid metabolism Am. J. Clin. Nutr., 68 (1998),pp. 72-81
[81]	Valayannopoulos, V., Baruteau, J., Delgado, M.B. et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study Orphanet J. Rare Dis., 11 (2016),p. 32
[82]	van Calcar, S.C., MacLeod, E.L., Gleason, S.T. et al. Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids Am. J. Clin. Nutr., 89 (2009),pp. 1068-1077
[83]	van Karnebeek, C.D., Jaggumantri, S. Current treatment and management of pyridoxine-dependent epilepsy Curr. Treat. Options Neurol., 17 (2015),p. 335
[84]	van Spronsen, F.J., de Groot, M.J., Hoeksma, M. et al. Large neutral amino acids in the treatment of PKU: from theory to practice J. Inherit. Metab. Dis., 33 (2010),pp. 671-676
[85]	Vockley, J., Burton, B., Berry, G.T. et al. UX007 for the treatment of long chain-fatty acid oxidation disorders: safety and efficacy in children and adults following 24 weeks of treatment Mol. Genet. Metab., 120 (2017),pp. 370-377
[86]	Vockley, J., Charrow, J., Ganesh, J. et al. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders Mol. Genet. Metab., 119 (2016),pp. 223-231
[87]	Vockley, J., Marsden, D., McCracken, E. et al. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment–a retrospective chart review Mol. Genet. Metab., 116 (2015),pp. 53-60
[88]	Wasserstein, M.P., Andriola, M., Arnold, G. et al. Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State Genet. Med., 18 (2016),pp. 1235-1243
[89]	Wolf, B. Successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening Genet. Med., 19 (2017),pp. 396-402
[90]	Yasui, T., Suzuki, T., Hara, F. et al. Successful living donor liver transplantation for classical maple syrup urine disease Pediatr. Transplant., 20 (2016),pp. 707-710
[91]	Yin, H., Xue, W., Chen, S. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype Nat. Biotechnol., 32 (2014),pp. 551-553
[92]	Yuzyuk, T., Thomas, A., Viau, K. et al. Effect of dietary lysine restriction and arginine supplementation in two patients with pyridoxine-dependent epilepsy Mol. Genet. Metab., 118 (2016),pp. 167-172